Herbalife

(

HLF

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.8%. By the end of trading, Herbalife rose $1.02 (1.7%) to $62.36 on heavy volume. Throughout the day, 3.9 million shares of Herbalife exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $60.15-$63.40 after having opened the day at $61.36 as compared to the previous trading day's close of $61.34. Other companies within the Drugs industry that increased today were:

Momenta Pharmaceuticals Inc

(

MNTA

), up 20.9%,

Cormedix Inc

(

CRMD

), up 16.7%,

Zalicus Inc

(

ZLCS

), up 15.8%, and

Complete Genomics Inc

(

GNOM

), up 14%.

Herbalife Ltd., a network marketing company, sells weight management, nutritional supplement, energy, sports and fitness, and personal care products worldwide. Herbalife has a market cap of $6.7 billion and is part of the

health care

sector. The company has a P/E ratio of 20, above the average drugs industry P/E ratio of 19.8 and above the S&P 500 P/E ratio of 17.7. Shares are up 72.6% year to date as of the close of trading on Friday.

TheStreet Ratings rates Herbalife as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front,

NPS Pharmaceuticals Inc

(

NPSP

), down 33.4%,

BioSpecifics Technologies Corporation

(

BSTC

), down 10.9%,

WuXi PharmaTech (Cayman) Inc

(

WX

), down 10.7%, and

Auxilium Pharmaceuticals Inc

(

AUXL

), down 9.6%, were all losers within the drugs industry with

Teva Pharmaceutical Industries

(

TEVA

) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null